Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Amicus Therapeutics Inc shares valued at $79,492 were sold by Campbell Bradley L on Oct 01 ’24. At $10.60 per share, Campbell Bradley L sold 7,500 shares. The insider’s holdings dropped to 886,654 shares worth approximately $9.31 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, BRADLEY CAMPBELL purchased 7,500 shares, netting a total of over 80,100 in proceeds.
Before that, Campbell Bradley L had sold 7,500 shares from its account. In a trade valued at $87,798, the President and CEO traded Amicus Therapeutics Inc shares for $11.71 each. Upon closing the transaction, the insider’s holdings decreased to 7,500 shares, worth approximately $9.31 million.
As published in their initiating research note from Jefferies on September 06, 2024, Amicus Therapeutics Inc [FOLD] has been a Buy and the price target has been revised to $18. Analysts at Wells Fargo started covering the stock with ‘”an Overweight”‘ outlook in a report released in late May. As of May 14, 2024, Guggenheim has increased its “Neutral” rating to a “Buy” for FOLD. Earlier on December 19, 2023, Morgan Stanley upgraded its rating. Their new recommendation was “an Overweight” for FOLD stock which previously was a “an Equal-weight”.
Analyzing FOLD Stock Performance
During the last five days, there has been a surge of approximately 3.35%. Over the course of the year, Amicus Therapeutics Inc shares have dropped approximately -26.00%. Shares of the company reached a 52-week high of $14.53 on 01/02/24 and a 52-week low of $9.02 on 05/13/24. A 50-day SMA is recorded $11.11, while a 200-day SMA reached $11.24. Nevertheless, trading volume fell to 1.73 million shares from 2.69 million shares the previous day.
Support And Resistance Levels for Amicus Therapeutics Inc (FOLD)
According to the 24-hour chart, there is a support level at 10.34, which, if violated, would cause prices to drop to 10.17. In the upper region, resistance lies at 10.63. The next price resistance is at 10.75. RSI (Relative Strength Index) is 45.60 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.02, which suggests the price will decrease in the coming days. Percent R is at 37.95%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.
